|
| 37537088 | A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma. | Clin Genitourin Cancer | 2024 |
| 38087711 | Interruptions in bladder cancer care during the COVID-19 public health emergency. | Urol Oncol | 2024 |
| 36007724 | Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial. | Int J Radiat Oncol Biol Phys | 2023 |
| 37553435 | The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. | Prostate Cancer Prostatic Dis | 2023 |
| 36403677 | Perioperative Nephrectomy Outcomes for Patients with Liver Disease: Implications for Liver Transplant Candidates. | Urology | 2023 |
| 36644811 | Readmissions after radical nephrectomy in a national cohort. | Scand J Urol | 2023 |
| 36397716 | Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer. | Cancer Med | 2023 |
| 36682700 | Contemporary Systemic Therapies in Urothelial Carcinoma. | Urology | 2023 |
| 36574911 | Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort. | Urology | 2023 |
| 34433303 | Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. | J Urol | 2022 |
| 35351369 | Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma. | Urol Oncol | 2022 |
| 34985341 | Reply by Authors. | J Urol | 2022 |
| 35302627 | Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. | JAMA Netw Open | 2022 |
| 34866018 | Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. | Clin Genitourin Cancer | 2022 |
| 31411981 | Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. | Eur Urol Oncol | 2021 |
| 33908802 | The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. | J Urol | 2021 |
| 33640225 | The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy. | Urol Oncol | 2021 |
| 34964855 | Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. | JAMA Netw Open | 2021 |
| 34805743 | Treatment Patterns, Outcomes, and Costs Associated With Localized Upper Tract Urothelial Carcinoma. | JNCI Cancer Spectr | 2021 |
| 34389428 | When is a Seminoma not a Seminoma? The Incidence, Risk Factors and Management of Patients With Testicular Seminoma With Discordant Elevated Serum Alpha-fetoprotein. | Urology | 2021 |
| 34121427 | Reply by Authors. | J Urol | 2021 |
| 34228501 | The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply. | J Urol | 2021 |
| 33243961 | Risk factors for penile fracture compared with a surgical control cohort in the United States: the role of substance abuse. | Asian J Androl | 2021 |
| 33347775 | Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. | J Urol | 2021 |
| 32778476 | "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. | Urol Oncol | 2021 |
| 33012575 | Trends in management of ureteral urothelial carcinoma and effects on survival: a hospital-based registry study. | Urol Oncol | 2021 |
| 32779081 | Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review. | J Gastrointest Surg | 2021 |
| 31537483 | Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. | Urol Oncol | 2020 |
| 32072229 | The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy. | World J Urol | 2020 |
| 33258891 | Urinary Diversion. | JAMA | 2020 |
| 33201207 | Bladder Cancer: A Review. | JAMA | 2020 |
| 33201205 | Bladder Cancer. | JAMA | 2020 |
| 32861253 | Analysis of guideline recommended use of renal mass biopsy and association with treatment. | Can J Urol | 2020 |
| 32631491 | Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. | Lancet Oncol | 2020 |
| 32925563 | A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. | J Immunother | 2020 |
| 32446641 | Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival. | Urol Oncol | 2020 |
| 32387291 | Sodium Fluorescein for Identification of Intraoperative Urine Leaks During Partial Nephrectomy. | Urology | 2020 |
| 32516030 | The Role of Opioids and Their Receptors in Urological Malignancy: A Review. | J Urol | 2020 |
| 32430252 | Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. | Urol Oncol | 2020 |
| 30467596 | Diagnostic biomarkers in non-muscle invasive bladder cancer. | World J Urol | 2019 |
| 32071562 | Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage. | Rev Urol | 2019 |
| 31411998 | Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. | Eur Urol Oncol | 2019 |
| 31306670 | Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty. | Urology | 2019 |
| 31017086 | Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. | Eur Urol Oncol | 2019 |
| 30790015 | Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. | Cancer Immunol Immunother | 2019 |
| 30930099 | Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. | Urol Oncol | 2019 |
| 30900065 | Second primary lung cancer in United States Cancer Survivors, 1992-2008. | Cancer Causes Control | 2019 |
| 30684034 | SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. | World J Urol | 2019 |
| 30267197 | Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. | World J Urol | 2019 |
| 30593457 | Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer. | Cancer Epidemiol Biomarkers Prev | 2019 |